Daiichi Sankyo says that, on its integrated data analysis platform, it provides an environment in which employees who are not engineers or data scientists can search and analyze clinical-trial information in everyday language by incorporating AI functions.
Jazz's 2025 sustainability report says the company introduced MOMENTUM in 2025, a clinical trial toolbox for patient-representation insights. It says MOMENTUM draws on large language model technology to help teams design more representative trials and recruit patient populations that reflect true disease epidemiology.
Takeda programmers presented a framework that uses an LLM through Amazon Bedrock to review ADaM specifications and generate SAS code.
Partners: AWS
BeOne's 2026 shareholder letter says the company's in-house development model has integrated AI and automation, and that BeOne is expanding the use of AI to optimize clinical trial design and accelerate recruitment. The same passage says the company has already shortened protocol-development time, sped proof-of-concept decisions and improved clinical-trial site monitoring.
Astellas said that using Evinova's AI-native Study Designer will enable it to design more sophisticated, patient-centered clinical trials efficiently. In the question session, the R&D head described that study designer as a platform on which AI agents discuss protocol design.
Partners: Evinova
Shionogi says the Artificial Intelligence Statistical Programming System, released in September 2023, enables AI to automatically generate the SAS statistical analysis programs required for clinical trials and achieved a 30% reduction in standard work hours.
30% reduction in standard work hours company-reported
Alnylam said it is partnering with Viz.ai to develop an AI-enabled ATTR-CM care pathway that combines an FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity. The release says the related AWARE study will launch at five pilot health systems later in 2026 to generate real-world evidence.
Partners: Viz.ai
AstraZeneca, alongside Astellas and BMS, agreed to use and share operational data with Evinova's AI-native trial platform (an AstraZeneca health-tech business) to get benchmarks and recommendations that speed trials.
Partners: Evinova
An AWS case study says CSL's Deviation AI uses AI-powered analytics to find deviations or outliers in trial outcomes so those trials can be evaluated and adjusted faster. The same page says the data platform that will support this work will be operational, so this is not described as already live.
A Lilly speaker at AWS re:Invent 2025 described a multi-agent system that lets non-technical staff query healthcare datasets in plain language, shortening data evaluation from months to weeks.
data evaluation time from ~4 months to under 4 weeks company-reported
Partners: AWS
Merck's data science and RWE groups agreed to use Atropos Health's platform and services to generate real-world evidence faster.
Partners: Atropos Health
Immunai announced a multi-year collaboration with Teva in immunology and immuno-oncology. Immunai says the work will use its AI model, the Immunodynamics Engine, for clinical-trial decisions including mechanism of action, dose selection and biomarker analyses.
Partners: Immunai
A custom GPT that uses ChatGPT Enterprise's data-analysis features to help review clinical data for dose selection.
Partners: OpenAI
Pfizer extended its agreement with Saama to scale an AI-driven clinical data quality tool across its wider global study portfolio.
Partners: Saama
Incyte's 2022 global responsibility report says patients in its vitiligo clinical trials have an AI-driven tool for tracking progress. It says a smartphone app launched in 2022 lets patients and healthcare providers capture, share, compare and review results, and that the Vitiligo Assessment Tool uses machine learning to analyze skin images for changes in skin characteristics.
GSK says it will work with Tempus, using Tempus's AI/ML capability and de-identified patient data, to improve clinical trial design, speed up enrolment and identify drug targets. GSK made a $70 million initial payment.
$70 million initial payment company-reported
Partners: Tempus
The same prospectus says Roivant aggregated clinical-trial technologies at its subsidiary Lokavant. It says algorithms trained on operational metadata from over 2,000 trials are designed to identify the most important risks in time for researchers to intervene, and that Lokavant's software is in use in Roivant's late-stage trials and in trials run by other sponsors and contract research organizations.
operational metadata from over 2,000 trials company-reported
UCB says its Statistical Science and Innovation group filed a patent application centred on an improved machine learning method that allows AI to predict an outcome or provide decision guidance, and that this innovation has already been used to inform patient stratification, clinical trial design and precision-medicine approaches in Parkinson's disease and epilepsy.